Compare · MRK vs PRTA
MRK vs PRTA
Side-by-side comparison of Merck & Company Inc. (MRK) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $358.21B, about 820.9x PRTA ($436.4M).
- MRK has been more active in the news (16 items in the past 4 weeks vs 7 for PRTA).
- MRK has more recent analyst coverage (25 ratings vs 22 for PRTA).
- Company
- Merck & Company Inc.
- Prothena Corporation plc
- Price
- $145.96+0.46%
- $8.36-1.70%
- Market cap
- $358.21B
- $436.4M
- 1M return
- -
- -1.18%
- 1Y return
- -
- -15.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 7
- Recent ratings
- 25
- 22
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest MRK
- SEC Form 8-K filed by Merck & Company Inc.
- Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
- Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
- CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Latest PRTA
- SEC Form 4 filed by Prothena Corporation plc
- SEC Form 4 filed by Prothena Corporation plc
- SEC Form 4 filed by Prothena Corporation plc
- Prothena Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Large owner Scully William P bought $1,405,674 worth of Ordinary Shares (162,000 units at $8.68) (SEC Form 4)
- Large owner Scully William P bought $889,872 worth of Ordinary Shares (103,500 units at $8.60) (SEC Form 4)
- Large owner Scully William P bought $843,460 worth of Ordinary Shares (100,000 units at $8.43), increasing direct ownership by 12% to 927,000 units (SEC Form 4)
- Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Large owner Scully William P bought $255,739 worth of Ordinary Shares (27,000 units at $9.47), increasing direct ownership by 3% to 827,000 units (SEC Form 4)
- Large owner Scully William P bought $439,430 worth of Ordinary Shares (50,000 units at $8.79), increasing direct ownership by 7% to 800,000 units (SEC Form 4)